Medical Weight Loss for Sparks, Nevada Residents
Sparks, Nevada residents get physician-supervised weight loss by telehealth from New Hope Weight Loss: a $119 doctor review, then compounded semaglutide from $166/month or tirzepatide from $233/month.
Physician-supervised GLP-1 programs from $166/month · just $5.50/day, serving Sparks through telehealth from our Costa Mesa, California clinic. Doctor review $119. Over 5,400 patients treated.
Why Sparks Residents Choose New Hope Weight Loss
Sparks patients choose New Hope Weight Loss because a named physician, Dr. Anjmun Sharma, M.D., oversees every case, pricing is transparent (semaglutide from $166/month, tirzepatide from $233/month · just $7.70/day), and the entire program runs by telehealth from our Costa Mesa, California clinic, which has served over 5,400 patients across Nevada and beyond since 2020.
Sparks patients are cared for entirely through telehealth from our Costa Mesa, California clinic. There is no travel, your consultation with Dr. Sharma, prescription, and follow-ups all happen by secure video.
Patients across Sparks and the surrounding area connect with Dr. Sharma by secure video, wherever they live in Nevada. We care for patients throughout the greater Sparks area and the Reno-Tahoe region. There is no distance surcharge for Sparks patients, and HSA, FSA, Klarna, and Affirm are all accepted.
Our telehealth model serves Sparks and communities across Nevada with the same flat pricing and the same supervising physician. The first step is a $119 physician review; if you are not a candidate you are not charged, and compounded semaglutide starts at $166/month.
GLP-1 Weight Loss Programs Available
Two GLP-1 programs for Sparks
Compounded semaglutide starts at $166/month (a 90-day program is $499) and uses the same active ingredient as Wegovy® and Ozempic®, which produced 15-17% average body-weight loss in clinical trials. Compounded tirzepatide starts at $233/month and uses a dual GLP-1/GIP mechanism shown to reach up to 22.5% in trials.
Every plan begins with a $119 physician review. Medication is billed separately, and HSA, FSA, Klarna, and Affirm are all accepted, with no distance surcharge.
How Telehealth Works for Sparks
1. Tell us your history through the quiz or intake form. 2. Dr. Sharma confirms your eligibility by secure video, usually within 48 hours. 3. Your compounded medication arrives at your Sparks address in cold-pack packaging, with ongoing follow-up from the team, all without leaving home.
Frequently Asked Questions, Sparks
How do I get treatment from Sparks?
As a Sparks, Nevada patient you connect with our Costa Mesa, California clinic by telehealth. Dr. Sharma oversees your plan by secure video and compounded medication ships to your home; eligibility is confirmed during the consultation.
Can I do this without an in-person visit from Sparks?
Yes, it is fully telehealth. Your review, prescription, and follow-up are remote, with medication shipped to Sparks in cold-pack packaging, no lines and no drive.
How much does it cost for Sparks patients?
A $119 physician review, then compounded semaglutide from $166/month or tirzepatide from $233/month (medication separate). HSA, FSA, Klarna, and Affirm are accepted, and there is never a distance surcharge.
What areas of Sparks do you serve?
We serve patients from across Sparks by telehealth, including the greater Sparks area and the Reno-Tahoe region.
Is my health information private as a Sparks patient?
Yes. Your intake, video visits, and records are handled under HIPAA safeguards, and medication arrives in discreet packaging. Sparks patients get the same confidentiality as any telehealth patient.
New Hope Weight Loss | clinic at 1503 South Coast Drive, Suite 322, Costa Mesa, CA 92626 | (657) 837-3342 | Serving Sparks, Nevada by telehealth. Telehealth availability and eligibility are confirmed during the medical consultation.
Wegovy® and Ozempic® are registered trademarks of Novo Nordisk A/S. Mounjaro® and Zepbound® are registered trademarks of Eli Lilly and Company. New Hope Weight Loss is not affiliated with or endorsed by these companies. Compounded semaglutide and tirzepatide are prepared by licensed U.S. pharmacies and are not FDA-approved, not brand-identical, and not reviewed by the FDA for safety, effectiveness, or quality.